Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation
2011 (English)In: Transplant International, ISSN 0934-0874, E-ISSN 1432-2277, Vol. 24, no 8, e61-e66 p.Article in journal (Refereed) Published
We describe the presumably first intentional ABO-incompatible deceased-donor kidney and pancreas transplantation with a severe antibody-mediated rejection during a rebound of isoagglutinins. Rejection was successfully treated with eculizumab, which inhibits the terminal pathway of complement. Complement analysis (C3, C3d,g, and a modified assay of classical complement-related hemolytic function) documented complement activation and confirmed that eculizumab completely blocked complement function. At 6 months, the patient had normal kidney and pancreas function, and histological evaluations revealed no evidence of sustained graft damage. This successful transplantation suggests that ABO barriers can safely be overcome without extensive preconditioning, when the complement inhibitor eculizumab is included.
Place, publisher, year, edition, pages
2011. Vol. 24, no 8, e61-e66 p.
ABO-incompatible pancreas and kidney transplantation, accommodation, complement activation, Eculizumab
Research subject Pathology
IdentifiersURN: urn:nbn:se:uu:diva-155664DOI: 10.1111/j.1432-2277.2011.01290.xISI: 000292462000001PubMedID: 21696455OAI: oai:DiVA.org:uu-155664DiVA: diva2:427444